AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication
While CAR-T therapies could vastly improve outcomes in some types of blood cancer, finding ways to replicate this effectively and safely in solid tumours remains a challenge.